La Commission européenne accorde une autorisation de mise sur le marché au LIVMARLI pour le traitement de la PFIC chez les patients âgés de...
Die Europäische Kommission erteilt LIVMARLI die Marktzulassung für die Behandlung von PFIC bei Patienten ab einem Alter von drei Monaten. Die...
European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older. Approval follows positive...
Submission based on the positive Phase 3 RESTORE study Mirum holds orphan designation for chenodiol in CTX Potential to have first and only...
- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of...
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim...
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on June 10, 2024, the Compensation Committee of Mirum’s Board of Directors...
- Daten belegen anhaltenden klinischen Nutzen nach siebenjähriger Behandlung mit LIVMARLI bei Patienten mit Alagille-Syndrom - Langfristige...
- Data showcases sustained clinical benefit following seven years of LIVMARLI treatment in patients with Alagille syndrome - Long-term extension...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and...
Positive CHMP-Stellungnahme auf der Grundlage der Phase-3-Studie MARCH mit statistisch hochsignifikanter (p<0,0001) Verringerung des...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.